Burkitt Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
CD20 positive	Burkitt Lymphoma	CD20 positive	Burkitt Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	CODOX-M + rituximab Sensitive: A2 - Guideline CODOX-M + rituximab Sensitive : A2	CODOX-M + rituximab Sensitive: A2 - Guideline CODOX-M + rituximab Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	R-CVAD Sensitive: A2 - Guideline R-CVAD Sensitive : A2	R-CVAD Sensitive: A2 - Guideline R-CVAD Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	R-CVAD + cytarabine + methotrexate Sensitive: A2 - Guideline R-CVAD + cytarabine + methotrexate Sensitive : A2	R-CVAD + cytarabine + methotrexate Sensitive: A2 - Guideline R-CVAD + cytarabine + methotrexate Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	EPOCH-R Sensitive: A2 - Guideline EPOCH-R Sensitive : A2	EPOCH-R Sensitive: A2 - Guideline EPOCH-R Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	R-GDP Sensitive: A2 - Guideline R-GDP Sensitive : A2	R-GDP Sensitive: A2 - Guideline R-GDP Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	RICE Sensitive: A2 - Guideline RICE Sensitive : A2	RICE Sensitive: A2 - Guideline RICE Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	RIVAC + methotrexate Sensitive: A2 - Guideline RIVAC + methotrexate Sensitive : A2	RIVAC + methotrexate Sensitive: A2 - Guideline RIVAC + methotrexate Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	RIVAC Sensitive: A2 - Guideline RIVAC Sensitive : A2	RIVAC Sensitive: A2 - Guideline RIVAC Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	RICE + methotrexate Sensitive: A2 - Guideline RICE + methotrexate Sensitive : A2	RICE + methotrexate Sensitive: A2 - Guideline RICE + methotrexate Sensitive : A2
LDH elevation	Burkitt Lymphoma	LDH elevation	Burkitt Lymphoma	ViPOR Sensitive: C3 – Early Trials ViPOR Sensitive : C3	ViPOR Sensitive: C3 – Early Trials ViPOR Sensitive : C3
TP53 T175H + PIK3CA H1047R	Burkitt Lymphoma	TP53 T175H + PIK3CA H1047R	Burkitt Lymphoma	cytarabine + ifosfamide + etoposide IV + methotrexate + dexamethasone Sensitive: C4 – Case Studies cytarabine + ifosfamide + etoposide IV + methotrexate + dexamethasone Sensitive : C4	cytarabine + ifosfamide + etoposide IV + methotrexate + dexamethasone Sensitive: C4 – Case Studies cytarabine + ifosfamide + etoposide IV + methotrexate + dexamethasone Sensitive : C4
TP53 T175H + PIK3CA H1047R	Burkitt Lymphoma	TP53 T175H + PIK3CA H1047R	Burkitt Lymphoma	idelalisib Sensitive: C4 – Case Studies idelalisib Sensitive : C4	idelalisib Sensitive: C4 – Case Studies idelalisib Sensitive : C4
TP53 A159V	Burkitt Lymphoma	TP53 A159V	Burkitt Lymphoma	PZ01 Sensitive: C4 – Case Studies PZ01 Sensitive : C4	PZ01 Sensitive: C4 – Case Studies PZ01 Sensitive : C4
CD19 positive + CD20 positive	Burkitt Lymphoma	CD19 positive + CD20 positive	Burkitt Lymphoma	rituximab + FT596 Sensitive: D – Preclinical rituximab + FT596 Sensitive : D	rituximab + FT596 Sensitive: D – Preclinical rituximab + FT596 Sensitive : D
LY9 expression	Burkitt Lymphoma	LY9 expression	Burkitt Lymphoma	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D
CD38 positive	Burkitt Lymphoma	CD38 positive	Burkitt Lymphoma	Actinium-225 conjugated to daratumumab Sensitive: D – Preclinical Actinium-225 conjugated to daratumumab Sensitive : D	Actinium-225 conjugated to daratumumab Sensitive: D – Preclinical Actinium-225 conjugated to daratumumab Sensitive : D
SLC1A5 overexpression	Burkitt Lymphoma	SLC1A5 overexpression	Burkitt Lymphoma	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D	MEDI7247 Sensitive: D – Preclinical MEDI7247 Sensitive : D

Burkitt Lymphoma

Associations(20)

Associations
(20)